Many Investors Still Treating Gilead: 4 Launches This Year Could Prove Them Wrong
Gilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
Using savings to pay off debt effectively can lighten your financial load. Explore strategies that can help you manage your debt wisely.
21,556 articlesGilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
Two quiet winners in the consumer space show how durable brands can compound wealth for generations. This article bre...
When a big investor deploys tens of millions into a biotech name ahead of an FDA decision, it can signal strong convi...
As Kolibri wraps its Q4 2025 results, investors seek clarity on growth, margins, and cash flow. This article translat...
Kick off the holiday with a focused investing reading list. This Friday Juneteenth reads roundup blends market insigh...
What separates a thriving growth story from a market-ready bubble? This guide breaks down concrete signals, offers a ...
When a gold stock soars 200%, even savvy investors reconsider risk. This article breaks down why trimming a large pos...
IBM has delivered a multiyear rally, but a 2026 pullback creates a buying opportunity for patient investors. This gui...
Micron stock has surged on AI tailwinds, but powerful under-the-radar forces could extend the rally. This article exp...
As Micron prepares for its quarterly update, investors face a crossroads between potential volatility and opportunity...
On Mondays, market indexes often tilt toward tech as AI momentum and cloud demand steal the spotlight. Industrials te...
Explore the 2026 earnings outlook for Quanex (NX) with a clear, investor-friendly analysis. Learn what drives results...